Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
JX Li, CL Cummins - Nature Reviews Endocrinology, 2022 - nature.com
Glucocorticoid hormones were discovered to have use as potent anti-inflammatory and
immunosuppressive therapeutics in the 1940s and their continued use and development …
immunosuppressive therapeutics in the 1940s and their continued use and development …
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
CF Deacon - Nature Reviews Endocrinology, 2020 - nature.com
Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update
L Blonde, GE Umpierrez, SS Reddy, JB McGill… - Endocrine Practice, 2022 - Elsevier
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement
KW Davidson, MJ Barry, CM Mangione, M Cabana… - Jama, 2021 - jamanetwork.com
Importance An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5%
meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in …
meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in …
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes …
AJ Garber, Y Handelsman, G Grunberger, D Einhorn… - Endocrine Practice, 2020 - Elsevier
ABSTRACT Abbreviations: A1C= hemoglobin A1C; AACE= American Association of Clinical
Endocrinologists; ABCD= adiposity-based chronic disease; ACCORD= Action to Control …
Endocrinologists; ABCD= adiposity-based chronic disease; ACCORD= Action to Control …
Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures–2019 update: cosponsored …
JI Mechanick, C Apovian, S Brethauer… - Surgery for Obesity and …, 2020 - Elsevier
Objective The development of these updated clinical practice guidelines (CPG) was
commissioned by the American Association of Clinical Endocrinologists, The Obesity …
commissioned by the American Association of Clinical Endocrinologists, The Obesity …
American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus
G Grunberger, J Sherr, M Allende, T Blevins, B Bode… - Endocrine practice, 2021 - Elsevier
Objective To provide evidence-based recommendations regarding the use of advanced
technology in the management of persons with diabetes mellitus to clinicians, diabetes-care …
technology in the management of persons with diabetes mellitus to clinicians, diabetes-care …
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and …
Y Handelsman, PS Jellinger, CK Guerin… - Endocrine practice, 2020 - Elsevier
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical
activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders …
activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders …
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
RE Pratley, VR Aroda, I Lingvay… - The lancet Diabetes & …, 2018 - thelancet.com
Background Despite common mechanisms of actions, glucagon-like peptide-1 receptor
agonists differ in structure, pharmacokinetic profile, and clinical effects. This head-to-head …
agonists differ in structure, pharmacokinetic profile, and clinical effects. This head-to-head …
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes …
MS Capehorn, AM Catarig, JK Furberg, A Janez… - Diabetes & …, 2020 - Elsevier
Aims SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent
semaglutide dose (1.0 mg) with the current most frequently prescribed liraglutide dose in …
semaglutide dose (1.0 mg) with the current most frequently prescribed liraglutide dose in …